<DOC>
	<DOCNO>NCT00048074</DOCNO>
	<brief_summary>This study ass efficacy safety intravenous administration Bonviva regimens woman post-menopausal osteoporosis , compare oral daily administration . Patients also receive daily supplementation vitamin D calcium . The anticipated time study treatment 2+ year , target sample size 500+ individual .</brief_summary>
	<brief_title>DIVA Study - A Study Different Regimens Intravenous Administration Bonviva ( Ibandronate ) Women With Post-Menopausal Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>woman 5580 year age ; postmenopausal &gt; =5 year ; ambulatory . malignant disease diagnose within previous 10 year ( except basal cell cancer successfully remove ) ; breast cancer within previous 20 year ; allergy bisphosphonates ; previous treatment intravenous bisphosphonate time ; previous treatment oral bisphosphonate within last 6 month , &gt; 1 month treatment within last year , &gt; 3 month treatment within last 2 year .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>